What is the VelocImmune® technology?

VelocImmune® is Regeneron's proprietary technology designed for the discovery of human monoclonal antibodies, allowing for faster and more efficient development of potential therapeutics.

What are the financial terms of the agreement?

AstraZeneca will pay Regeneron $20 million upfront, with potential for up to five additional annual payments of $20 million each, subject to certain performance and termination clauses. Regeneron will also receive mid-single-digit royalties on future sales of products developed using the technology.

Does this agreement give AstraZeneca full rights to the VelocImmune® technology?

No, the agreement is non-exclusive, meaning Regeneron can license its VelocImmune® technology to other parties as well.

What is the significance of this deal for Regeneron?

This agreement validates the strength and commercial potential of Regeneron's VelocImmune® technology, providing immediate non-dilutive funding ($20 million upfront) and the possibility of future royalty revenue, which can significantly contribute to the company's financial resources and R&D efforts.

REGN 8-K: Material Agreements

Summary

Regeneron Pharmaceuticals, Inc. (REGN) announced on February 5, 2007, a significant non-exclusive license agreement with AstraZeneca. This agreement grants AstraZeneca rights to utilize Regeneron's proprietary VelocImmune® technology for the discovery of human monoclonal antibodies. The deal represents a material definitive agreement, highlighting Regeneron's success in monetizing its innovative technological platforms.

Key Highlights

1Regeneron entered into a non-exclusive license agreement with AstraZeneca on February 5, 2007.
2The agreement grants AstraZeneca rights to use Regeneron's VelocImmune® technology for antibody discovery.
3AstraZeneca will make an upfront payment of $20 million to Regeneron.
4AstraZeneca may make up to five additional annual payments of $20 million, subject to certain conditions and termination rights.
5Regeneron is eligible to receive mid-single-digit royalties on future sales of antibody products developed using the VelocImmune® technology.
6This agreement showcases the commercial value and potential of Regeneron's VelocImmune® platform.

REGENERON PHARMACEUTICALS, INC. 8-K Report, Material Agreement (Feb 6, 2007)

Summary

Key Highlights

Frequently Asked Questions